NO20005290L - Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom - Google Patents

Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom

Info

Publication number
NO20005290L
NO20005290L NO20005290A NO20005290A NO20005290L NO 20005290 L NO20005290 L NO 20005290L NO 20005290 A NO20005290 A NO 20005290A NO 20005290 A NO20005290 A NO 20005290A NO 20005290 L NO20005290 L NO 20005290L
Authority
NO
Norway
Prior art keywords
riluzole
disease
parkinson
treatment
levodopa
Prior art date
Application number
NO20005290A
Other languages
English (en)
Other versions
NO20005290D0 (no
NO329032B1 (no
Inventor
Veronique Blanchard-Bregeon
Assunta Imperato
Saliha Moussaoui
Marie-Carmen Obinu
Michel Reibaud
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20005290D0 publication Critical patent/NO20005290D0/no
Publication of NO20005290L publication Critical patent/NO20005290L/no
Publication of NO329032B1 publication Critical patent/NO329032B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
NO20005290A 1998-04-24 2000-10-20 Kombinasjon av riluzol- og levodopa samt anvendelse derav NO329032B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9805153A FR2777781B1 (fr) 1998-04-24 1998-04-24 Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
PCT/FR1999/000953 WO1999055336A1 (fr) 1998-04-24 1999-04-22 Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson

Publications (3)

Publication Number Publication Date
NO20005290D0 NO20005290D0 (no) 2000-10-20
NO20005290L true NO20005290L (no) 2000-10-20
NO329032B1 NO329032B1 (no) 2010-08-02

Family

ID=9525640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005290A NO329032B1 (no) 1998-04-24 2000-10-20 Kombinasjon av riluzol- og levodopa samt anvendelse derav

Country Status (22)

Country Link
US (1) US6387936B1 (no)
EP (1) EP1071422B1 (no)
JP (1) JP2002512963A (no)
KR (1) KR100597170B1 (no)
AT (1) ATE386520T1 (no)
AU (1) AU768069B2 (no)
CA (1) CA2329636C (no)
CY (1) CY1110448T1 (no)
CZ (1) CZ300825B6 (no)
DE (1) DE69938179T2 (no)
DK (1) DK1071422T3 (no)
ES (1) ES2300141T3 (no)
FR (1) FR2777781B1 (no)
HU (1) HU228902B1 (no)
IL (1) IL139164A (no)
NO (1) NO329032B1 (no)
PT (1) PT1071422E (no)
RU (1) RU2225204C2 (no)
SK (1) SK285531B6 (no)
UA (1) UA70319C2 (no)
WO (1) WO1999055336A1 (no)
ZA (1) ZA200005758B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
EP1746985A4 (en) * 2004-05-21 2010-08-11 Univ Duke METHOD FOR INCREASING THE EFFECT OF SEROTONINE RECOVERY INHIBITORS
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
PL1817006T3 (pl) * 2004-11-07 2013-03-29 F Timothy Guilford Liposomalny preparat do doustnego podawania glutationu (zredukowanego)
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2363124B1 (en) * 2006-06-28 2016-02-17 Lundbeck NA Ltd Pharmaceutical compositions comprising droxidopa
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008226541B2 (en) * 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2514417A3 (en) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
MX2010014222A (es) * 2008-06-30 2011-03-29 Novartis Ag Star Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
US20100160295A1 (en) * 2008-11-06 2010-06-24 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма

Also Published As

Publication number Publication date
DE69938179T2 (de) 2009-02-12
US6387936B1 (en) 2002-05-14
CZ20003908A3 (cs) 2001-02-14
ZA200005758B (en) 2002-01-17
PT1071422E (pt) 2008-05-05
JP2002512963A (ja) 2002-05-08
SK285531B6 (sk) 2007-03-01
CA2329636C (fr) 2009-09-08
CA2329636A1 (fr) 1999-11-04
FR2777781A1 (fr) 1999-10-29
NO20005290D0 (no) 2000-10-20
CY1110448T1 (el) 2015-04-29
IL139164A0 (en) 2001-11-25
AU3425599A (en) 1999-11-16
DE69938179D1 (de) 2008-04-03
KR100597170B1 (ko) 2006-07-05
NO329032B1 (no) 2010-08-02
WO1999055336A1 (fr) 1999-11-04
ATE386520T1 (de) 2008-03-15
RU2225204C2 (ru) 2004-03-10
KR20010042960A (ko) 2001-05-25
DK1071422T3 (da) 2008-06-16
SK15882000A3 (sk) 2001-04-09
HUP0101645A2 (hu) 2001-09-28
EP1071422A1 (fr) 2001-01-31
HUP0101645A3 (en) 2002-10-28
AU768069B2 (en) 2003-12-04
ES2300141T3 (es) 2008-06-01
FR2777781B1 (fr) 2004-04-09
UA70319C2 (en) 2004-10-15
EP1071422B1 (fr) 2008-02-20
HU228902B1 (en) 2013-06-28
IL139164A (en) 2005-12-18
CZ300825B6 (cs) 2009-08-19

Similar Documents

Publication Publication Date Title
NO20005290D0 (no) Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom
GB0108592D0 (en) Therapeutic agents
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
PL310475A1 (en) Application of anticonvulsants in treating neuro-aids diseases
BG106450A (en) Use of retigabin for treating neuropathic pain
SI1303272T1 (sl) Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni
FI20000720A7 (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
DE69832695D1 (de) Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
HUP9904029A3 (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis
EA200000816A1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
ATE323486T1 (de) Verwendung des riluzols oder dessen salzen zur phophylaxe und behandlung der adrenoleukodystrophie
NO970190D0 (no) Preparat til behandling av Parkinsons sykdom

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees